Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 835 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 835 shares of the business’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $42.00, for a total transaction of $35,070.00. Following the transaction, the director now owns 334,646 shares in the company, valued at $14,055,132. This represents a 0.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pro-Dex Price Performance

Shares of PDEX opened at $40.66 on Friday. The firm has a market capitalization of $132.55 million, a PE ratio of 26.40 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The company’s 50-day moving average is $47.87 and its 200-day moving average is $33.56. Pro-Dex, Inc. has a fifty-two week low of $16.18 and a fifty-two week high of $59.60.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th. Ascendiant Capital Markets boosted their target price on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its position in shares of Pro-Dex by 5.1% in the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares during the last quarter. Geode Capital Management LLC boosted its stake in Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares during the period. JPMorgan Chase & Co. grew its holdings in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after buying an additional 529 shares in the last quarter. Bard Associates Inc. increased its position in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after buying an additional 900 shares in the last quarter. 15.28% of the stock is owned by institutional investors.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.